Drugs in Dev. Ophthalmology
Phase III
Canada 
Lead Product(s) : Atropine
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Eyenovia
Deal Size : Undisclosed
Deal Type : Acquisition
Eyenovia Re-Acquires Development Rights To Micropine in U.S. and Canada
Details : Eyenovia re-acquired rights to MicroPine in the U.S. and Canada, expanding its phase III pipeline, being evaluated as a potential treatment for pediatric progressive myopia.
Product Name : MicroPine
Product Type : Other Small Molecule
Upfront Cash : $5.0 million
January 16, 2024
Lead Product(s) : Atropine
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Eyenovia
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Perfluorohexyloctane
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Novaliq
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : NOV03 (Perfluorohexyloctane) is the first drug developed to treat dry eye disease associated with Meibomian gland dysfunction in a highly effective way. It stabilizes the lipid layer for hours to protect the tear film and has the ability to penetrate the...
Product Name : NOV03
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 01, 2023
Lead Product(s) : Perfluorohexyloctane
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Novaliq
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Perfluorohexyloctane
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Novaliq
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : NOV03 (perfluorohexyloctane) Ophthalmic Soluton, is an investigational, proprietary, water-free, single-component preservative-free eye drop , an investigational treatment with a proposed indication of treating the signs and symptoms of dry eye disease.
Product Name : NOV03
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 07, 2022
Lead Product(s) : Perfluorohexyloctane
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Novaliq
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Perfluorohexyloctane
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Novaliq
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : NOV03 (perfluorohexyloctane) A potential first-in-class eye drop with a novel mechanism of action, NOV03 is an investigational therapy to treat the signs and symptoms of dry eye disease (DED) associated with Meibomian gland dysfunction (MGD).
Product Name : NOV03
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 09, 2022
Lead Product(s) : Perfluorohexyloctane
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Novaliq
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Perfluorohexyloctane
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Presentations include results from Phase 3 trials of investigational NOV03 (perfluorohexyloctane), as well as from several studies involving products from company's consumer health care, pharmaceutical and surgical portfolios, such as XIPERE for supracho...
Product Name : NOV03
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 28, 2022
Lead Product(s) : Perfluorohexyloctane
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Perfluorohexyloctane
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : NOV03 (perfluorohexyloctane) is being investigated as a first-in-class treatment with a novel mechanism of action to treat the signs and symptoms of dry eye disease (DED) associated with Meibomian gland dysfunction (MGD).
Product Name : NOV03
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 05, 2022
Lead Product(s) : Perfluorohexyloctane
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Perfluorohexyloctane
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Novaliq
Deal Size : Inapplicable
Deal Type : Inapplicable
Bausch + Lomb Completes Enrollment Of Second Phase 3 Study For NOV03 (Perfluorohexyloctane)
Details : The Phase 3 program for NOV03 also includes a previous Phase 3, multi-center, randomized, double-masked, saline-controlled trial (GOBI), for which the companies announced statistically significant topline results in April 2021.
Product Name : NOV03
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 07, 2021
Lead Product(s) : Perfluorohexyloctane
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Novaliq
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Triamcinolone Acetonide
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Bausch + Lomb Will Present New Scientific Data And Analyses On Products And Pipeline Programs
Details : The virtual presentations will feature several of the company's prominent products from its pharmaceutical, surgical and vision care portfolios, including analyses on the company's investigational drug XIPERE™ (triamcinolone acetonide suprachoroidal in...
Product Name : Xipere
Product Type : Hormone
Upfront Cash : Inapplicable
April 29, 2021
Lead Product(s) : Triamcinolone Acetonide
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Perfluorohexyloctane
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Novaliq
Deal Size : Inapplicable
Deal Type : Inapplicable
Bausch + Lomb Completes Enrollment of First Phase 3 Study for NOV03 (Perfluorohexyloctane)
Details : First of two Phase 3 studies evaluating NOV03 as an investigational drug with a novel mechanism of action to treat the signs and symptoms of Dry eye disease associated with Meibomian gland dysfunction has been completely enrolled with a total of 599 part...
Product Name : NOV03
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 19, 2021
Lead Product(s) : Perfluorohexyloctane
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Novaliq
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Perfluorohexyloctane
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : NOV03 is an investigational, proprietary, water-free and preservative-free solution, based on patented EyeSol® technology from Novaliq GmbH1. DED is a chronic and serious disease of the ocular surface.
Product Name : NOV03
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 24, 2020
Lead Product(s) : Perfluorohexyloctane
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
